Download This Document
Download This Document
The 2021 SRS Acquiom Life Sciences Study analyzes deal terms from more than 295 life sciences transactions that have been closed for more than one year, including milestone achievement data on 218 deals that have earnouts (aggregate $52.1B up-front plus $59.6B earnout potential).
The study provides data by industry sector, up-front value, closing year, and product stage and presents proprietary insights, including:
How much earnout potential is in near-term milestones versus long-term “biodollars”?
How much do parties typically negotiate for milestones at each phase of development?
Which milestones actually get paid, and when?
Did COVID-19 have an impact on life sciences milestones and earnouts?
Since 2008, SRS Acquiom has provided professional and financial services for life sciences M&A transactions involving biotech/pharmaceutical products (Bio/Pharma), medical devices, diagnostics, and life sciences tools and technologies. Very few of these agreements or information on post-closing outcomes are available publicly.
Head of Life Sciences 303.250.8936
Don advises life science clients on M&A deal negotiations and post-closing milestones and earnouts. He is principal author of our life science studies and a frequent speaker at industry events.
Before joining SRS Acquiom, Don spent more than a decade helping to grow two venture-backed life science start-up companies through IPOs. He has been responsible for many strategic transactions involving licensing, partnering and M&A, as well as financings with leading venture capital and private equity firms. He was formerly SVP, Corporate Development and General Counsel for Replidyne, an antibiotic drug development company, and VP, Legal Affairs and Business Development for Caliper Life Sciences, a microfluidics company. He began his career as a business attorney with Cooley LLP.
Don holds a law degree from USC and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado.
Managing Director, Professional Services Group tel:415-363-6081
Casey is a managing director at SRS Acquiom and leads the Professional Services group. His team of lawyers, accountants, and other professionals is responsible for managing post-closing escrow claims, earnouts, working capital, tax, and other disputes on behalf of the company's clients, post-closing distribution of merger proceeds, and other activities related to serving as the shareholder representative. While at SRS Acquiom, Casey has represented shareholders’ interests on hundreds of deals, including defending claims up to $400 million and administering life sciences deals with as much as $1 billion in contingent consideration.
Before joining SRS Acquiom, Casey represented Fortune 50 clients as a litigation attorney nationally and internationally in a variety of fields. He acted as outside counsel on behalf of numerous parties, including SRS Acquiom and its clients, and took multiple cases to trial and appeal.
Casey frequently presents and writes on subjects of interest to those in the M&A field and is a core contributor to SRS Acquiom’s life sciences study. He is also an Eagle Scout and volunteers with San Francisco Bay Area youth sports. He holds a J.D. from the University of California, Berkeley (Boalt Hall) and a B.S. in economics from Arizona State University’s Barrett Honors College.